<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01839188</url>
  </required_header>
  <id_info>
    <org_study_id>V419-010</org_study_id>
    <secondary_id>2012-004221-25</secondary_id>
    <secondary_id>PRI02C</secondary_id>
    <nct_id>NCT01839188</nct_id>
  </id_info>
  <brief_title>Spanish Mixed HEXA/PENTA/HEXA Schedule</brief_title>
  <official_title>A Phase 3 Open-label Study to Evaluate the Immunogenicity and Safety of a Mixed (HEXA/PENTA/HEXA) Primary Series Schedule That Includes V419 (PR5I) at 2 and 6 Months of Age and Pediacel at 4 Months of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MCM Vaccines B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the immune response and the safety of a primary series schedule that includes
      V419 (PR5I) at 2 and 6 months of age and Pediacel at 4 months of age

      Primary objectives

        -  To demonstrate that the mixed schedule induces acceptable responses for Hepatitis B one
           month after completion of the mixed schedule

        -  To demonstrate that the mixed schedule induces acceptable responses for Hib one month
           after completion of the mixed schedule

      Secondary objectives

        -  To describe the antibody response to all PR5I antigens one month after completion of the
           mixed schedule

        -  To describe the antibody response to meningococcal serogroup C (MenC) conjugate vaccine
           one month after the second dose of MenC vaccine

        -  To describe the safety profile after each dose of study vaccines administered
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with an anti-hepatitis B titre ≥10 mIU/mL</measure>
    <time_frame>Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with an anti-polyribosylribitol phosphate (PRP) titre ≥0.15 µg/mL</measure>
    <time_frame>Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an anti-diphtheria concentration ≥0.01 IU/mL</measure>
    <time_frame>Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an anti-tetanus concentration ≥0.01 IU/mL</measure>
    <time_frame>Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an anti-inactivated poliovirus 1 titre ≥1:8 dil</measure>
    <time_frame>Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an anti-inactivated poliovirus 2 titre ≥1:8 dil</measure>
    <time_frame>Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an anti-inactivated poliovirus 3 titre ≥1:8 dil</measure>
    <time_frame>Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers for pertussis</measure>
    <time_frame>Month 7 (one month after the complete mixed schedule PR5I/Pediacel/PR5I)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an anti-MenC titre ≥ 1:8dil</measure>
    <time_frame>Month 5 (one month after the second dose of MenC vaccine)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited injection-site reactions and systemic adverse events</measure>
    <time_frame>Day 1 to Day 5 following vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited injection-site and systemic adverse events</measure>
    <time_frame>Day 1 to Day 15 following vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>From signature of the informed consent to the last visit of the subject, an expected average of 5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">385</enrollment>
  <condition>Neisseria Meningitidis</condition>
  <condition>Bacterial Infections</condition>
  <condition>Virus Diseases</condition>
  <arm_group>
    <arm_group_label>PR5I/Pediacel/PR5I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PR5I/Pediacel/PR5I mixed schedule with concomitant Prevenar 13 / NeisVac-C / RotaTeq</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PR5I (V419)</intervention_name>
    <description>Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b conjugate [Meningococcal Outer Membrane Protein Complex], and hepatitis B [Recombinant] Vaccine 0.5 mL intramuscular injection at 2 and 6 months of age</description>
    <arm_group_label>PR5I/Pediacel/PR5I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pediacel</intervention_name>
    <description>Adsorbed diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus influenzae type b conjugate vaccine 0.5 mL intramuscular injection at 4 months of age</description>
    <arm_group_label>PR5I/Pediacel/PR5I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NeisVac-C</intervention_name>
    <description>Meningococcal group C polysaccharide conjugate vaccine adsorbed 0.5 mL intramuscular injection at 2 and 4 months of age</description>
    <arm_group_label>PR5I/Pediacel/PR5I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RotaTeq</intervention_name>
    <description>Human-bovine rotavirus reassortants (live) vaccine 2mL oral administration at 2, 4 and 6 month</description>
    <arm_group_label>PR5I/Pediacel/PR5I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar 13</intervention_name>
    <description>Pneumococcal conjugate vaccine (13-valent, adsorbed) 0.5 mL intramuscular injection at 2 and 4 months of age</description>
    <arm_group_label>PR5I/Pediacel/PR5I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infant 46 to 74 days (both inclusive)

          -  Documented receipt of only one dose of monovalent hepatitis B vaccine within the 3
             days after birth

          -  Parent(s)/legal representative able to comply with the study procedures

        Exclusion Criteria:

          -  Participation in any study with an investigational compound or device since birth

          -  History of congenital or acquired immunodeficiency

          -  Chronic illness that could interfere with study conduct or completion

          -  Hypersensitivity to any of the study vaccines components or history of a
             life-threatening reaction to a vaccine containing the same substances as the study
             vaccines

          -  Contraindication to Pediacel, NeisVac-C, Prevenar 13, and RotaTeq

          -  History or maternal history of HBsAg seropositivity

          -  Coagulation disorder that contraindicate intramuscular injection

          -  History of vaccination with a Haemophilus influenzae type b conjugate, diphtheria,
             tetanus, pertussis (acelullar or whole-cell), poliovirus, meningococcal serogroup C
             conjugate, pneumococcal conjugate containing vaccine(s)

          -  History of hepatitis B, Haemophilus influenzae type b, diphtheria, tetanus, pertussis,
             poliomyelitis, or serogroup C meningococcal infection

          -  Receipt of immune globulin, blood or blood-derived products since birth

          -  Receipt of systemic corticosteroids for more than 14 consecutive days within one month
             of the study start

          -  Identified as a natural or adopted child of the Investigator or employee with direct
             involvement in the proposed study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Days</minimum_age>
    <maximum_age>76 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 004</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 015</name>
      <address>
        <city>Almeria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 016</name>
      <address>
        <city>Almeria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 012</name>
      <address>
        <city>Burriana</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 010</name>
      <address>
        <city>Cuart de Poblet</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 008</name>
      <address>
        <city>La Eliana</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 011</name>
      <address>
        <city>Paiporta</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 003</name>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 001</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 014</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 006</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 007</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 009</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 013</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 005</name>
      <address>
        <city>Vilagarcia de Arousa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2013</study_first_submitted>
  <study_first_submitted_qc>April 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2013</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

